Etanercept 25mg; per vial (pwd for SC inj after reconstitution; preservative-free; diluent contains benzyl alcohol); 25mg/0.5mL, 50mg/mL prefilled syringe (soln for SC inj; preservative free); 50mg/mL prefilled syringe SureClick autoinjector (soln for SC inj; preservative-free); 50mg/mL Enbrel Mini prefilled cartridge (soln for use with AutoTouch autoinjector only; preservative-free).
Etanercept treatment is well tolerated for psoriasis, with no indication of dose-related or cumulative toxicity in short- or long-term analyses.
ACR/ARHP Annual Meeting 2015
The efficacy and safety profiles of SB4, an etanercept biosimilar, were comparable to those of etanercept in patients with moderate to severe rheumatoid arthritis (RA) to Week 52, according to study findings presented at the 2015 ACR/ARHP Annual Meeting.
First-line etanercept-methotrexate would result in 0.15 additional lifetime QALY, at cost of 77,290
Ustekinumab had highest effectiveness during five years of tx; more dose escalation for etanercept
ACR/ARHP Annual Meeting 2013
A post-hoc analysis of two trials found patients with active psoriatic arthritis treated with etanercept with or without methotrexate combination therapy had similar clinical and functional outcomes at 24 weeks of treatment, researchers concluded at the 2013 ACR/ARHP Annual Meeting.
For patients with rheumatoid arthritis (RA), long-term clinical outcomes are good with etanercept and adalimumab; but for adalimumab, treatment response is strongly dependent on the presence or absence of anti-adalimumab antibodies.
Reich, K et al. "Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials." DOI: http://dx.doi.org/10.1016/S0140-6736(17)31279-5
Drugs in the Pipeline
Lilly announced positive results from two Phase 3 studies, UNCOVER-2 and UNCOVER-3, of ixekizumab for the treatment of moderate-to-severe plaque psoriasis compared to etanercept or placebo. Study findings were recently presented at the American Academy of Dermatology (AAD) Annual Meeting in Washington, D.C.
For patients with psoriasis, ustekinumab is more effective than tumor necrosis factor-α inhibitors, according to a study published in the Journal of the American Academy of Dermatology.